Anti-cancer PEG-enzymes: 30 years old, but still a current approach

Advanced Drug Delivery Reviews

Volumn 60, Issue 1, 2008, Pages 69-78

  Pasut, Gianfranco ^a   Sergi, Mauro ^b   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Bio Ker   (Italy)

Author keywords

Anti cancer enzymes; Arginase; Arginine deiminase; Asparaginase; Methioninase; Uricase

Indexed keywords

CHEMOTHERAPY; DRUG DELIVERY; DRUG PRODUCTS; ENZYME ACTIVITY; ONCOLOGY; PROTEINS;

ANTI-CANCER ENZYMES; ARGININE DEIMINASE; ASPARAGINASE; METHIONINASE;

POLYETHYLENE GLYCOLS;

ANTINEOPLASTIC AGENT; ARGINASE; ARGININE DEIMINASE; ASPARAGINASE; ASPARAGINASE MACROGOL; ENZYME; FLUOROURACIL; MACROGOL; MACROGOL 20000; METHIONINE GAMMA LYASE; URATE OXIDASE;

CANCER; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG PURIFICATION; HUMAN; LIVER CELL CARCINOMA; MELANOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; ENZYMES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 36549004553     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.04.018     Document Type: Review

References (84)

1. Capdevilel R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev., Drug. Discov. 7 (2002) 493-502
2. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev., Cancer 6 (2006) 688-701
3. Langer C.J. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer 6 Suppl. 2 (2004) S85-S88
4. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21 (1999) 309-318
5. Abuchowski A., van Es T., Palczuk N.C., and Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252 (1977) 3578-3581
6. In: Veronese F.M., and Harris J.M. (Eds). Theme issue on "Peptide and Protein Pegylation I". Ad. Drug Del. Rev vol. 54 (2002) 453-609
7. Veronese F.M., and Harris J.M. Theme issue on "Pegylation of peptides and proteins II - Clinical Evaluation". Ad. Drug Del. Rev vol. 55 (2003) 1259-1350
8. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1457
9. Vellard M. The enzyme as drug: application of enzymes as pharmaceuticals. Curr. Opin. Biotechnol. 14 (2003) 444-450
10. Cairo M.S. Prevention and treatment of hyperuricemia in hematological malignancies. Clin. Lymphoma 3 Suppl 1 (2002) S26-S31
11. Pu C.H. Rasburicase: a potent uricolytic agent. Expert Opin. Pharmacother. 3 (2002) 433-442
12. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. Exp. Med. 98 (1953) 565-582
13. Broome J.D. Evidence that the l-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the l-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J. Exp. Med. 118 (1963) 99-120
14. Campbell H.A., and Mashburn L.T. l-Asparaginase EC-2 from Escherichia coli. Some substrate specificity characteristics. Biochemistry 8 (1969) 3768-3775
15. Whelan H.A., and Wriston Jr. J.C. Purification and properties of asparaginase from Escherichia coli B. Biochemistry 8 (1969) 2386-2393
16. Taylor C.W., Dorr R.T., Fanta P., Hersh E.M., and Salmon S.E. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated l-asparaginase in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 47 (2001) 83-88
17. Agrawal N.R., Bukowski R.M., Rybicki L.A., Kurtzberg J., Cohen L.J., and Hussein M.A. A Phase I-II trial of polyethylene glycol-conjugated l-asparaginase in patients with multiple myeloma. Cancer 98 (2003) 94-99
18. Abuchowski A., van Es T., Palczuk N.C., McCoy J.R., and Davis F.F. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic l-glutaminase-l-asparaginase. Cancer Treat. Rep. 63 (1979) 1127-1132
19. Park Y.K., Abuchowski A., Davis S., and Davis F. Pharmacology of Escherichia coli-l-asparaginase polyethylene glycol adduct. Anticancer Res. 1 (1981) 373-376
20. Abuchowski A., Kazo G.M., Verhoest Jr. C.R., Van Es T., Kafkewitz D., Nucci M.L., Viau A.T., and Davis F.F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7 (1984) 175-186
21. Ho D.H., Brown N.S., Yen A., Holmes R., Keating M., Abuchowski A., Newman R.A., and Krakoff I.H. Clinical pharmacology of polyethylene glycol-l-asparaginase. Drug Metab. Dispos. 14 (1986) 349-352
22. Soares A.L., Guimaraes G.M., Polakiewicz B., de Moraes Pitombo R.N., and Abrahao-Neto J. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli l-asparaginase. Int. J. Pharm. 237 (2002) 163-170
23. Kurtzberg J. In: Gansler T. (Ed). Cancer Medicine. 5th ed (2000), M. Decker Inc, Canada
24. Avramis V.I., and Panosyan E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin. Pharmacokinet. 44 (2005) 93-367
25. Davis F.F. PEG-adenosine deaminase and PEG-asparaginase. Adv. Exp. Med. Biol. 519 (2003) 51-58
26. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55 (2003) 1293-1302
27. Kurre H.A., Ettinger A.G., Veenstra D.L., Gaynon P.S., Franklin J., Sencer S.F., Reaman G.H., Lange B.J., and Holcenberg J.S. A pharmacoeconomic analysis of PEG-aspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the children's cancer group study (CCG-1962). J. Pediatr. Hematol./Oncol. 24 (2002) 175-181
28. Hawkins D.S., Park J.R., Thomson B.G., Felgenhauer J.L., Holcenberg J.S., Panosyan E.H., and Avramis V.I. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated l-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin. Cancer Res. 10 (2004) 5335-5341
29. Panosyan E.H., Seibel N.L., Martin-Aragon S., Gaynon P.S., Avramis I.A., Sather H., Franklin J., Nachman J., Ettinger L.J., La M., Steinherz P., Cohen L.J., Siegel S.E., and Avramis V.I. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children's cancer group study CCG-1961. J. Pediatr. Hematol./Oncol. 26 (2004) 217-226
30. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., and Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110 (2007) 103-111
31. Hoffman R.M., and Jacobsen S.J. Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 7306-7310
32. Guo H., Herrera H., Groce A., and Hoffman R.M. Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res. 53 (1993) 2479-2483
33. 6-methylguanine DNA methyltransferase by methionine in human tumor cells. Br. J. Cancer 75 (1997) 779-788
34. Guo H., Lishko V.K., Herrera H., Groce A., Kubota T., and Hoffman R.M. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res. 53 (1993) 5676-5679
35. Cellarier E., Durando X., Vasson M.P., et al. Methionine dependency and cancer treatment. Cancer Treat. Rev. 29 (2003) 489-499
36. Tan Y., Xu M., Tan X., Wang X., Saikawa Y., Nagahama T., Sun X., Lenz M., and Hoffman R.M. Overexpression and large-scale production of recombinant l-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Protein Expr. Purif. 9 (1997) 233-245
37. Tan Y., Zavala Sr J., Xu M., Zavala Jr. J., and Hoffman R.M. Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients. Anticancer Res. 16 (1996) 3937-3942
38. Tan Y., Zavala Sr J., Han Q., Xu M., Sun X., Tan X., Magana R., Geller J., and Hoffman R.M. Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res. 17 (1997) 3857-3860
39. Sun X., Yang Z., Li S., Tan Y., Zhang N., Wang X., Yagi S., Yoshioka T., Takimoto A., Mitsushima K., Suginaka A., Frenkel E.P., and Hoffman R.M. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5-phosphate supplementation. Cancer Res. 63 (2003) 8377-8383
40. Tan Y., Sun X., Xu M., An Z., Tan X., Han Q., Miljkovic D.A., Yang M., and Hoffman R.M. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expr. Purif. 12 (1998) 45-52
41. Yang Z., Wang J., Yoshioka T., Li B., Lu Q., Li S., Sun X., Tan Y., Yagi S., Frenkel E.P., and Hoffman R.M. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin. Cancer Res. 10 (2004) 2131-2138
42. Yang Z., Sun X., Li S., Tan Y., Wang X., Zhang N., Yagi S., Takakura T., Kobayashi Y., Takimoto A., Yoshioka T., Suginaka A., Frenkel E.P., and Hoffman R.M. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5-phosphate. Cancer Res. 64 (2004) 5775-5778
43. Yang Z., Wang J., Lu Q., Xu J., Kobayashi Y., Takakura T., Takimoto A., Yoshioka T., Lian C., Chen C., Zhang D., Zhang Y., Li S., Sun X., Tan Y., Yagi S., Frenkel E.P., and Hoffman R.M. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 64 (2004) 6673-6678
44. Sugimura K., Ohno T., Kusuyama T., and Azuma I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res. 2 (1992) 191-196
45. Cheng P.N., Leung Y.C., Lo W.H., Tsui S.M., and Lam K.C. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett. 224 (2005) 67-80
46. Savoca K.V., Abuchowski A., van Es T., Davis F.F., and Palczuk N.C. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochim. Biophys. Acta 578 (1979) 47-53
47. Misawa S., Aoshima M., Takaku H., Matsumoto M., and Hayashi H. High level expression of Mycoplasma arginine deiminase in Escherichia coli and its efficient renaturation as an anti-tumor enzyme. J. Biotechnol. 36 (1994) 145-155
48. Takaku H., Takase M., Abe S., Hayashi H., and Miyazaki K. In vivo antitumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer 51 (1992) 244-249
49. Gong H., Zolzer F., von Recklinghausen G., Havers W., and Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14 (2000) 826-829
50. Ensor C.M., Holtsberg F.W., Bomalaski J.S., and Clark M.A. PEGylated argininedeiminase (ADI-SS PEG 20,000 MW) inhibits human melanomas and hepatocellularcarcinomas in vitro and in vivo. Cancer Res. 62 (2002) 5443-5450
51. Durden D.L., and Distasio J.A. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res. 40 (1980) 1125-1129
52. Distasio J.A., Salazar A.M., Nadji M., and Durden D.L. Glutaminase-freeasparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int. J. Cancer 30 (1982) 343-347
53. Holtsberg F.W., Ensor C.M., Steiner M.R., Bomalaski J.S., and Clark M.A. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J. Control. Release 80 (2002) 259-271
54. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., Cremona F., Ensor C.M., Holtsberg F.W., Bomalaski J.S., Clark M.A., Ng C., and Curley S.A. PEGylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J. Clin. Oncol. 22 (2004) 1815-1822
55. Ascierto P.A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J. Clin. Oncol. 23 (2005) 7660-7668 (Erratum in: J. Clin. Oncol.24 (2006) 4047)
56. Izzo F., Montella M., Orlando A.P., Nasti G., Beneduce G., Castello G., et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J. Gastroenterol. Hepatol. 22 (2007) 86-91
57. Wang M., Basu A., Palm T., Hua J., Youngster S., Hwang L., et al. Engineering an arginine catabolizing bioconjugate: biochemical and pharmacological characterization of pegylated derivatives of arginine deiminase from Mycoplasma arthritidis. Bioconjug. Chem. 17 (2006) 1447-1459
58. Weickmann J.L., and Fahrney D.E. Arginine deaminase from Mycoplasma arthritidis: evidence for multiple forms. J. Biol. Chem. 252 (1977) 2615-2620
59. Weickmann J.L., Himmel M.E., Squire P.G., and Fahrney D.E. Arginine deiminase from Mycoplasma arthritidis: properties of the enzyme from log phase cultures. J. Biol. Chem. 253 (1978) 6010-6015
60. Smith D.W., Ganaway R.L., and Fahrney D.E. Arginine deiminase from Mycoplasma arthritidis: structure-activity relationships among substrates and competitive inhibitors. J. Biol. Chem. 253 (1978) 6016-6020
61. Takaku H., Matsumoto M., Misawa S., and Miyazaki K. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth-inhibitory mechanism. Jpn. J. Cancer Res. 86 (1995) 840-846
62. Cheng P.N., Lam T., Lam W., Tsui S., Cheng A.W., Lo W., and Leung Y. Pegylated recombinant human arginase (rhArg-peg 5,000 MW) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 67 (2007) 309-317
63. Morris Jr. S.M. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22 (2002) 87-105
64. Savoca K.V., Davis F.F., van Es T., McCoy J.R., and Palczuk N.C. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia. Cancer Biochem. Biophys. 7 (1984) 261-268
65. Wheatley D.N., and Campbell E. Arginine catabolism, liver extracts and cancer. Pathol. Oncol. Res. 8 (2002) 18-25
66. N.M. Cheng, Y.C. Leung, W.H. Lo, Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation. US patent no. 20050244398. 2005 November 3.
67. Bayol A., Capdevielle J., Malazzi P., Buzy A., Claude Bonnet M., Colloc'h N., Mornon J.P., Loyaux D., and Ferrara P. Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural Aspergillus flavus uricase. Biotechnol. Appl. Biochem. 36 (2002) 21-31
68. Nishimura H., Ashihara Y., Matsushima A., and Inada Y. Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum. Enzyme 24 (1979) 261-264
69. Chen R.H., Abuchowski A., Van Es T., Palczuk N.C., and Davis F.F. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim. Biophys. Acta 660 (1981) 293-298
70. Davis S., Park Y.K., Abuchowski A., and Davis F.F. Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet 2 (1981) 281-283
71. Nishimura H., Matsushima A., and Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 26 (1981) 49-53
72. Caliceti P., Schiavon O., and Veronese F.M. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjug. Chem. 10 (1999) 638-646
73. Caliceti P., Schiavon O., and Veronese F.M. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug. Chem. 12 (2001) 515-522
74. Bomalaski J.S., Holtsberg F.W., Ensor C.M., and Clark M.A. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J. Rheumatol. 29 (2002) 1942-1949
75. Chua C.C., Greenberg M.L., Viau A.T., Nucci M., Brenckman Jr. W.D., and Hershfield M.S. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann. Int. Med. 109 (1988) 114-117
76. Schiavon O., Caliceti P., Ferruti P., and Veronese F.M. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). Farmaco 55 (2000) 264-269
77. M. Sherman, M. Saifer, L. Williams, Aggregate-free urate oxidase for preparation of non-immunogenic polymer-conjugates. US Patent no. 783,965 (2004).
78. Bomalaski J.S., and Clark M.A. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr. Rheumatol. Rep. 6 (2004) 240-247
79. Lukasheva E.V., and Berezov T.T. l-Lysine a-oxidase: physicochemical and biological properties. Biochemistry (Moscow) 67 10 (2002) 1394-1402
80. Kusakabe H., Kodama K., Kuninaka A., Yoshino H., and Soda K. A new antitumor enzyme, l-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J. Biol. Chem. 255 (1980) 976-981
81. Lay A.J., Jiang X., Kisker O., Flynn E., Underwood A., Condron R., and Hogg P.J. Phosphoglycerate kinase acts in tumor angiogenesis as a disulphide reductase. Nature 408 (2000) 869-873
82. O'Reilly M.S., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
83. Barak Y., Thorne S.H., Ackerley D.F., Lynch S.V., Contag C.H., and Matin A. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. Mol. Cancer Ther. 5 (2006) 97-103
84. Patterson A.V., Saunders M.P., and Greco O. Prodrugs in genetic chemo-radiotherapy. Curr. Pharm. Des. 9 (2003) 2131-2154